Get the app
USHealthcare

Avantor Inc (AVTR)

US · Healthcare · Medical Instruments & Supplies

$15.86+1.60%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$1.69B
Revenue YoY
+0.5%
Net profit
$38.1M
Profit YoY
-41.1%
EPS
$0.21
EPS estimate
$0.19
Net margin
2.3%

EPS came in at 0.21 against a street estimate of 0.19 — a beat of 10.5%.

Key statistics

Market cap
$10.06B
Forward P/E
17.0
P/B
1.79
Book value
$8.32
EPS (TTM)
$-0.85
52-week high
$15.93
52-week low
$7.26
50-day MA
$12.81
200-day MA
$10.41
Beta
0.90

Analyst view

Analysts rate Avantor Inc a buy (10 buy, 11 hold, 0 sell out of 21) with an average price target of $14.66.

From the latest earnings call · 2026-07-29

CONFIDENT Avantor's Revival transformation is gaining traction. VWR returned to 1.7% organic growth; BMP posted strong orders and margins despite discrete headwinds. FY26 EPS guidance raised to $0.80–$0.83; expects BMP growth return in H2. Q2 2026 U.S. pharma and biotech activity strong, especially large global customers. European education and certain segments remain soft. Analysts pressed on VWR growth attribution and sustainability (market vs. execution). Management emphasized majority from deliberate commercial actions, market-share recovery tools (pricing, digital, funnel management), and confirmed momentum acceleration expected H2. On BMP backlog conversion, team highlighted supply-chain productivity gains (25% throughput increases) as key lever. 2026-07-29…

Full summary in the app.

Shareholding

Insiders
1.50%
Institutions
105.43%

Largest institutional holders

FundStake
Dodge & Cox17.75%
BlackRock Inc9.71%
Vanguard Portfolio Management, LLC4.62%
Vanguard Capital Management, LLC4.53%
Greenhaven Associates Inc3.64%
State Street Corp3.06%
Dimensional Fund Advisors, Inc.3.02%
Engine Capital Management LP2.94%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
AVANTOR, INC. - Q2 2026 FORM 10-Q SUMMARY --- HEADLINE NUMBERS • Net Sales (6M 2026): $3,273.7 million vs. $3,264.8 million (6M 2025) — essentially
2026-07-29
Results announced · Q3 2026
AVANTOR Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net sales: $1,692.3 million, up 0.5% reported; organic decline of 0.4% • Net income: $38.1 milli
2026-07-29
Material agreement · Q3 2026
AVANTOR, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company obtained €374,208,296.62 in new senior secured Euro-denominated term loans on July 14, 2
2026-07-17
Shareholder vote results · Q2 2026
AVANTOR, INC. (AVTR) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 7, 2026 with stockholder votes on director elections, executive c
2026-05-12
Quarterly report · Q1 2026
AVANTOR, INC. - Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Net sales: $1,581.4 million (flat year-over-year vs. Q1 2025: $1,581.4 million) • Net i
2026-04-29
Results announced · Q2 2026
AVANTOR Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net sales: $1,581.4 million (flat vs. Q1 2025) • Organic net sales decline: 4.1% (foreign curren
2026-04-29
Proxy statement · Q2 2026
AVANTOR, INC. — 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGES • Emmanuel Ligner appointed President and CEO effective August 2025 (re
2026-03-27
Annual report FY2025
AVANTOR, INC. (AVTR) - 2025 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Fiscal Year Ended: December 31, 2025 • Stock Symbol: AVTR on New Yo
2026-02-11

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Avantor Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.